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Hematopoietic stem cell transplantation with HLA-DPB1emismatched donors leads to an increased risk of
acute graft-versus-host disease (GVHD). Studies have indicated a prognostic value for classifying HLA-DPB1
mismatches based on T celleepitope (TCE) groups. The aim of this study was to determine the contribu-
tion of indirect recognition of HLA-DPederived epitopes, as determined with the Predicted Indirectly
ReCognizable HLA Epitopes (PIRCHE) method. We therefore conducted a retrospective single-center analysis
on 80 patients transplanted with a 10/10 matched unrelated donor that was HLA-DPB1 mismatched. HLA-
DPB1 mismatches that were classiﬁed as GVH nonpermissive by the TCE algorithm correlated to higher
numbers of HLA class I as well as HLA class II presented PIRCHE (PIRCHE-I and -II) compared with permissive
or host-versus-graft nonpermissive mismatches. Patients with acute GVHD grades II to IV presented signif-
icantly higher numbers of PIRCHE-I compared with patients without acute GVHD (P < .05). Patients were
divided into 2 groups based on the presence or absence of PIRCHE. Patients with PIRCHE-I or -II have an
increased hazard of acute GVHD when compared with patients without PIRCHE-I or -II (hazard ratio [HR],
3.19; 95% conﬁdence interval [CI], 1.10 to 9.19; P < .05; and HR, 4.07; 95% CI, .97 to 17.19; P ¼ .06, respectively).
Patients classiﬁed as having an HLA-DPB1 permissive mismatch by the TCE model had an increased risk of
acute GVHD when comparing presence of PIRCHE-I with absence of PIRCHE-I (HR, 2.96; 95% CI, .84 to 10.39;
P ¼ .09). We therefore conclude that the data presented in this study describe an attractive and feasible
possibility to better select permissible HLA-DPB1 mismatches by including both a direct and an indirect
recognition model.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) with a
matched unrelated donor that is mismatched for HLA-DPB1
leads to an increased risk of acute graft-versus-host disease
(GVHD) [1-6]. It is well established that certain HLA-DP mis-
matches more frequently lead to this effect of T cellerelated
alloreactivity than others [2,5,6]. HLAmismatch-induced Tcell
alloreactivity can be evoked via 2 routes of mismatched an-
tigen recognition: direct and indirect recognition. Direct
recognition occurs when donor T cells recognize an intact
mismatched HLA molecule that is present on the cell surface
of a recipient’s cell. These directly recognizing T cells are likelydgments on page 1709.
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14.06.026viral peptide-speciﬁc memory T cells showing cross-reactivity
toward allogeneic HLA, due to molecular mimicry [7].
Direct recognition of HLA-DPmismatches can be predicted
with the T celleepitope (TCE) model, developed by Fleisch-
hauer et al. [2,5]. This TCE model is based on cross-reactivity
patterns of alloreactive T cells isolated from a patient that had
rejected his graft [2]. In this model, HLA-DPB1 alleles of donor
and recipient are divided into 3 (or 4) groups, either predicted
to have high, intermediate, or low immunogenic potential.
HLA-DPB1 mismatches are subsequently classiﬁed as
permissive or nonpermissive based on the concept of thymic
education of T cells. Mismatches are deﬁned as permissive if
they belong to the same immunogenicity group and as
nonpermissive if they belong to groups with different
immunogenicity. The direction of nonpermissiveness is based
on the direction of immunogenicity: when the recipient has a
higher TCE-assigned immunogenicity than the donor, mis-
matches are designated as GVH nonpermissive, whereasTransplantation.
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than the donor, the mismatch is designated as host-versus-
graft (HVG) nonpermissive. Several studies have shown that
HLA-DPB1mismatches classiﬁed as nonpermissive by the TCE
model are associated with both an increased risk of acute
GVHD [2,5,6] and an increased risk of overall mortality [5,6].
HLA molecules can also be recognized indirectly. Indirect
recognition has not been included in the TCE model. During
indirect recognition, donor T cells recognize polymorphic
peptides derived from the mismatched HLA molecule pre-
sented by an HLAmolecule that is shared between donor and
recipient. T cells speciﬁc for such polymorphic HLA-derived
peptides have been found frequently during graft failure af-
ter solid organ transplantation [8-12]. Indirect recognition
can be predicted in silico as well: Our group previously
developed a model that predicts the numbers of peptides
derived from mismatched HLA alleles that can be presented
by shared HLA. These peptides have been designated as
Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE)
[13-15]. Increasing numbers of PIRCHE are correlated to an
increased risk of alloreactivity, as reﬂected by increased
probabilities of acute GVHD after HSCT [15] and by the
development of donor-speciﬁc antibodies after kidney
transplantation [13].
We hypothesize that nonpermissibility of HLA-DPB1 mis-
matches can, next to the TCE model, be explained by indirect
recognition of the HLA-DPB1emismatched alleles. To inves-
tigate whether PIRCHE can indeed provide an additive
explanation for nonpermissibility of certain HLA-DPB1
mismatch combinations, the number of HLA-DPB1ederived
PIRCHEwas determined inpatients transplantedwith anHLA-
A, -B, -C, -DRB1, -DQB1 (10/10)-matched, HLA-DBP1emis-
matched unrelated donor. The numbers of PIRCHE were
studied for their correlation with permissiveness as deter-
mined by the TCE model and to clinical measures of allor-
eactivity (acute and chronic GVHD, relapse/progression of the
original disease, and transplant-related mortality [TRM]).METHODS
Patients
All adult patients receiving a peripheral blood stem cell transplantation
from a 10/10 (matched for HLA-A, -B, -C, -DRB1, -DQB1 on a 4-digit level)
matched unrelated donor after nonmyeloablative conditioning between
2007 and 2012 at the University Medical Center Utrecht were included in
this analysis (Supplementary Tables 1, 2, and 3). Nonmyeloablative condi-
tioning consisted of total body irradiation of 2 Gy for 1 day, antithymocyte
globulin (Genzyme, Cambridge,MA) 2mg/kg/day for 4 days, and ﬂudarabine
30 mg/m2/day for 3 days. Patients received an unmanipulated peripheral
blood stem cell graft. Immunosuppressive therapy consisted of cyclosporine
A 4.5 mg/kg twice daily until day 120, which was then tapered by a 10% dose
reduction per week in the absence of GVHD. Cyclosporine A was combined
with mycophenolate mofetil 15 mg/kg, 3 times a day until day 84; if there
was no GVHD, this regimenwas tapered and stopped in 2weeks. All patients
received antibiotic prophylaxis, including co-trimoxazole 480 mg twice a
day and valacyclovir 500 mg twice a day, as previously reported [16]. Mean
donor age was 36.5 years (range, 22 to 45), and disease stage before HSCT
was complete remission in 32 patients (40%), partial remission in 32 patients
(40%), progressive in 2 (3%), and not available for 14 patients (18%).HLA Typing
Sequencing-based high-resolution HLA typing was performed before
HSCT for all patients and donors for the HLA-A, -B, -C, -DRB1, and -DQB1 loci
by PCR and sequencing using the SBTexcellerator HLA-A, -B, -C, -DRB1, and
-DQB1 kits (GenDx, Utrecht, the Netherlands). Puriﬁed sequencing products
were electrophoresed using a 3730 DNA analyzer (Applied Biosystems,
Foster City, CA), and sequences were analyzed using SBTengine software
(GenDx). All protocols were executed according to manufacturers’ guide-
lines. All allele and genotype ambiguities at the 4-digit level were resolved,
and all null alleles were excluded.HLA-DPB1 typing was performed retrospectively using sequencing-
based typing (for the primers used see Supplementary Table 4). Homo-
zygotic typings were conﬁrmed with sequence-speciﬁc oligonucleotide
technologies (One Lambda, Canoga Park, CA). After HLA-DPB1 typing, am-
biguities could not be resolved for 18 individuals (11%). For all these unre-
solved ambiguities, the locations of the polymorphic residues were
analyzed. All polymorphisms were located outside positions affecting the
immunogenicity as predicted by the TCE model and were more than 9
amino acids apart. Consequently, all allelic combinations possiblewith these
ambiguities led to identical TCE and PIRCHE assignment. We therefore
included these pairs using their ambiguous HLA-DPB1 typings.TCE Classiﬁcation
HLA-DPB1 mismatches were classiﬁed as either permissive or nonper-
missive in the GVH or HVG direction, as described previously [2,5,6,17]. To
this end, HLA-DPB1 typing data were entered in the online tool available for
determining TCE groups (http://www.ebi.ac.uk/ipd/imgt/hla/dpb.html
[accessed January 2013]), which uses the TCE 3-group model. For 2
donorerecipient combinations (3%), permissiveness could not be deter-
mined with this tool, because one of their HLA-DPB1 alleles was not
included in the TCE model (HLA-DPB1*35:01 and DPB1*36:01).PIRCHE Determination
PIRCHE were identiﬁed for each donorerecipient pair as described
previously [14,15]. In short, for HLA class I presented PIRCHE (PIRCHE-I),
processing by the proteasome and transportation via the TAP channel of the
amino acid sequences of all donor and recipient HLA molecules (sequences
as deﬁned by international immunogenetics information system (IMGT):
ftp://ftp.ebi.ac.uk/pub/databases/ipd/imgt/hla [accessed December 2012])
was predicted using NetChop C-term 3.0 [18,19]. Predicted processed
nonameric peptides were tested for their binding capacity to the HLA class I
molecules using NetMHCpan 2.4 [20, 21]. Peptides with IC50 binding values
 500 nMwere accepted as relevant binders [22]. For HLA class II presented
PIRCHE (PIRCHE-II), the nonameric binding cores of potential HLA-DRB1
binders (15-mers) were predicted with NetMHCIIPan 2.0 [23-25] consid-
ering IC50 binding values  1000 nM as being relevant [26]. For each
donorerecipient pair, only unique recipient-speciﬁc peptideeHLA com-
plexes were counted as PIRCHE.Statistical Analyses
The primary clinical endpoint tested was incidence of acute GVHD
grades II to IV [27]. Secondary clinical endpoints were extensive or limited
chronic GVHD [16], relapse/progression of the primary malignant disease
(for patients transplanted for a malignant disease only, n¼ 76 {as deﬁned by
the HOVON study group [28-32]}), TRM, and overall survival.
Differences in distribution of PIRCHE in the TCE-assigned permissive
groups were tested with Mann-Whitney U tests comparing the 3 TCE groups
(HVG nonpermissive, GVH nonpermissive, and permissive) with each other.
These tests were also performed to compare the distribution of PIRCHE
among clinical outcomes.
Cumulative incidence curves were constructed for primary and sec-
ondary clinical endpoints. Relapse and nonrelapse mortality were regarded
as competing risks for acute GVHD, mortality related to relapse was regar-
ded as a competing risk for chronic GVHD, TRMwas regarded as a competing
risk for relapse, and mortality related to relapse and mortality due to other
causes were regarded as competing risks for TRM. Differences in cumulative
incidences were tested with the Gray test.
The time-dependent association of TCE-assigned nonpermissiveness
and numbers of PIRCHE with development of primary and secondary end-
points was tested with Cox regression analyses. Models were adjusted for
(when relevant) age of the recipient at transplantation, primary disease,
cytomegalovirus status, development of acute GVHD grades II to IV for
chronic GVHD, and development of acute and chronic GVHD for relapse.
Backward selection was used to determine which variables should be
included in the model; the likelihood ratio test was used to select the
relevant variables (P < .10). Variables were also included when they were
associated with the variable of interest (either TCE classiﬁcation or PIRCHE),
as tested with ANOVA for the continuous variable age and chi-square for
categorical variables: primary disease, gender, cytomegalovirus status, and
Epstein-Barr virus status (serostatus of both recipient and donor and the
match status between them).
Statistical procedures were performed with SPSS statistics software,
version 20.0 (SPSS Inc, Chicago, IL), and competing risk analyses were per-
formed with R version 3.0.0 (The R Foundation for Statistical Computing,
Vienna, Austria). P < .05 was considered to be statistically signiﬁcant.
Figure 1. Cumulative acute GVHD incidence curves for the 3 TCE classiﬁca-
tions. Although HVG (gray line) and GVH (dashed line) nonpermissive mis-
matches have a higher incidence of acute GVHD than permissive (black solid
line) mismatches, this was not signiﬁcantly different. Non-perm indicates
nonpermissive.
Table 1
Association of the TCE and PIRCHE Models with Acute GVHD
Variable HR 95% CI P
TCE model
GVH nonpermissive* 1.82 .68-4.87 NS
HVG nonpermissive* 1.37 .50-3.76 NS
PIRCHE-I
PIRCHE-I present 3.19 1.10-9.19 <.05
PIRCHE-II
PIRCHE-II present 4.07 .97-17.19 NS
PIRCHE-I within TCE permissive
PIRCHE-I present 2.96 .84-10.39 NS
Hazard ratios of the different TCE and PIRCHE groups as determined with
Cox regression analyses. Presence of PIRCHE-I was signiﬁcantly associated
with an increased hazard of acute GVHD compared with absence of PIRCHE-
I. There was a trend for an increased hazard of acute GVHD for presence
compared with absence of PIRCHE-II. Within the TCE permissive group,
presence of PIRCHE-I was associated with an increased hazard of acute
GVHD compared with absence PIRCHE-I. NS indicates not signiﬁcant.
* Reference: permissive mismatches.
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Within our cohort of 88 patients transplanted with 10/10-
matched unrelated donors within a uniform reduced-
intensity regimen [16], 8 recipients (9%) were transplanted
with an HLA-DPB1 matched donor. Of the 80 mismatched
pairs, 2 pairs (3%) could not be analyzed with the classical
direct recognition (TCE) model because for 1 of the alleles
immunogenicity could not be predicted. Of the remaining 78
pairs (97%) with a TCE designation, 54 (69%) were classiﬁed
as permissive, 12 (15%) as GVH nonpermissive, and 12 (15%)
as HVG nonpermissive (Supplementary Table 1). To assess
the impact of indirect recognition, the numbers of PIRCHE
were determined as described in Methods. Recipients pre-
sented amedian of 1 PIRCHE-I (range, 0 to 7) and 3.5 PIRCHE-
II (range, 0 to 20).
To correlate the presence of PIRCHE with clinical
outcome, donorerecipient pairs were divided into 2 PIRCHE
groups, according to the absence or presence of PIRCHE.
Baseline characteristics were evenly distributed among the
TCE groups and the absence or presence of PIRCHE, apart
from age at HSCT (patients with GVH nonpermissive mis-
matches were younger than those with HVG nonpermissive
or permissive mismatches; Supplementary Tables 1, 2,
and 3). Models testing TCE-assigned permissiveness were
therefore corrected for age at HSCT.
Correlation of the TCE Model with Acute GVHD
The correlation between direct recognition as predicted
with the TCE groups and acute GVHD was investigated with
univariate cumulative incidence analyses and in multivariate
Cox regression models. TCE permissive mismatches dis-
played the lowest incidence of acute GVHD, although the
cumulative incidences were not signiﬁcantly different
among the 3 TCE groups and not when comparing permis-
sive with GVH and HVG nonpermissive combined (Figure 1).
In multivariate analyses, which were corrected for age of the
recipient, TCE groups were not signiﬁcantly associated with
acute GVHD (Table 1).
Correlation of the PIRCHE Model with Acute GVHD
The inﬂuence of indirect recognition on acute GVHD was
assessed by correlating numbers of PIRCHE to the incidence
of acute GVHD grades II to IV. Recipients with acute GVHD
grades II to IV presented signiﬁcantly higher numbers of
PIRCHE-I (P ¼ .05) but not of PIRCHE-II (Figure 2A,B). When
analyzing the presence of PIRCHE, PIRCHE-I and -II were
signiﬁcantly associated with increased incidences of acute
GVHD comparedwith recipients without PIRCHE (P¼ .01 and
P¼ .04, respectively; Figure 2C,D). In Cox regression analyses,
the presence of PIRCHE-I was associated with an increased
hazard of acute GVHD compared with absence (hazard ratio
[HR], 3.19; 95% conﬁdence interval [CI], 1.10 to 9.19; P ¼ .03).
For PIRCHE-II there was a similar trend (HR, 4.07; 95% CI, .97
to 17.19; P ¼ .06; Table 1). Thus, the presence of PIRCHE is
correlated with increased acute GVHD risks.
Comparing the TCE and PIRCHE Models
To test whether the sensitivity of the direct recognition
(TCE) and indirect recognition (PIRCHE) models differ,
receiver operator characteristic curves were constructed and
the areas under the curve (AUC) calculated as a measure of
predictive capacity. Only PIRCHE-I signiﬁcantly predicted
acute GVHD (TCE AUC, .586, P ¼ .21; PIRCHE-I AUC, .641,
P ¼ .04; PIRCHE-II AUC, .580, P ¼ .25).To investigate the relationship between the TCE and
PIRCHE model, the correlation between the TCE groups and
numbers of PIRCHE was analyzed. Pairs with TCE-predicted
GVH nonpermissive mismatches had higher numbers of
PIRCHE-I when compared with both permissive or HVG
nonpermissive mismatches (P < .01). There was a nonsig-
niﬁcant increase in numbers of PIRCHE-II when comparing
GVH nonpermissive with permissive mismatches; however,
PIRCHE-II was signiﬁcantly higher in the GVH nonpermissive
group when compared with HVG nonpermissive (P < .01)
and signiﬁcantly lower in the HVG nonpermissive compared
with the permissive group (P ¼ .03). When analyzing the
presence of PIRCHE, the TCE permissive group contained 22
pairs (41%) without PIRCHE-I, 12 pairs (22%) without PIRCHE-
II, and 32 (59%) and 42 pairs (78%) with PIRCHE-I or PIRCHE-
II, respectively. The TCE and PIRCHE classiﬁcation are thus
correlated, although the PIRCHE model designates mis-
matches as nonpermissible when they are permissive
according to the TCE model.
To study whether the PIRCHE model can further deﬁne
HLA-DP mismatches, the correlation of PIRCHE with acute
GVHD within the TCE permissive mismatches was studied.
Figure 2. Boxplots showing the correlation between numbers of PIRCHE-I and acute GVHD (A) and the correlation between numbers of PIRCHE-II and acute GVHD
(B). Boxes represent the 25th to 75th percentile, the horizontal lines the median, and the whiskers all PIRCHE values from minimum to maximum. (C) Cumulative
acute GVHD incidence curves for the absence and presence of PIRCHE-I. (D) Cumulative acute GVHD incidence curves for the absence and presence of PIRCHE-II.
Recipients developing acute GVHD presented signiﬁcantly higher numbers of PIRCHE-I but not of PIRCHE-II. Cumulative incidence of acute GVHD was signiﬁ-
cantly increased for recipients presenting PIRCHE-I (gray line), compared with those without PIRCHE-I (solid line), similar for PIRCHE-II. *P < .05.
Figure 3. Cumulative acute GVHD incidence curves for the absence and
presence of PIRCHE-I within the TCE permissive group. Within the TCE
permissive group, recipients presenting PIRCHE-I (gray line) have an increased
probability (P ¼ .06) of acute GVHD compared with those without PIRCHE-I
(solid line).
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PIRCHE-I had a lower risk of acute GVHD when compared
with recipients with PIRCHE-I (HR, 2.96; 95% CI, .84 to 10.39;
P ¼ .09; Figure 3, Table 1). This effect was not observed for
PIRCHE-II. Of the 16 recipients (30%) who developed acute
GVHD despite the permissive TCE classiﬁcation, 13 (81%)
have PIRCHE-I and are thus more adequately classiﬁed by
PIRCHE-I. A similar strategy could not be performed for the
TCE nonpermissive group, because all recipients with GVH
nonpermissive mismatches have PIRCHE-I and -II, and there
were few patients without PIRCHE-I or -II in the HVG
nonpermissive group (5 and 4, respectively).
Secondary Endpoints
The TCE and PIRCHE models were studied for their cor-
relation with other clinical outcomes. Neither TCE non-
permissiveness nor PIRCHE were associated with an
increased hazard of chronic GVHD in multivariate models
corrected for cytomegalovirus, recipient age, and acute
GVHD development (data not shown). Neither the TCE
classiﬁcation nor the presence of PIRCHE were signiﬁcantly
associated with TRM in our cohort in multivariate models
that were corrected for the primary disease group and age of
the recipient (data not shown). In multivariate models, cor-
rected for age of the recipient and primary disease, neither
TCE nonpermissiveness nor the presence of PIRCHE was
associated with overall survival (data not shown).
The TCE model correlates to relapse; HVG nonpermissive
mismatches lead to a signiﬁcantly increased incidence of
relapse when compared with GVH nonpermissive mis-
matches or permissive mismatches (P ¼ .03 and P < .001,
respectively). In multivariate analyses, which were corrected
for the development of chronic GVHD and age of therecipient, HVG nonpermissive mismatches were clearly
associated with an increased hazard of relapse when
compared with permissive mismatches (HR, 3.71; 95% CI,
1.50 to 9.21; P < .01). PIRCHE were not correlated to relapse,
neither in univariate nor in multivariate analyses. To sum-
marize, TCE-assigned HVG nonpermissive mismatches are
correlatedwith an increased relapse risk, whereas PIRCHE do
not correlate with other endpoints than acute GVHD.
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HLA-DP mismatches are correlated to alloreactivity after
HSCT [1-6,33-36]. It is recognized that directly recognizable
HLA-DPB1 mismatches, as predicted with the TCE model,
correlate with inferior outcomes after HSCT [2,5,6,33]. The
present study was initiated to investigate whether indirectly
recognizable HLA-DPB1 mismatches predict nonpermissible
mismatches, next to the TCE model. In our local cohort of 10/
10-matched unrelated stem cell transplants, predicted indi-
rectly recognizable HLA-DPB1 mismatches, as determined
via the PIRCHE concept, indeed correlate with acute GVHD.
Moreover, our observations indicate that the PIRCHE model
is able to further deﬁne HLA-DP permissibility within the TCE
permissive group.
Despite a clear association between the TCE and PIRCHE
predictions, the PIRCHE model appears to more adequately
classify HLA-DPB1 mismatches as permissible and non-
permissible in vivo. These PIRCHE-predicted improvements
are likely explained by the lengths of the polymorphic parts
of the HLA-DPB1 alleles that are considered in both models.
The TCE model is based on polymorphisms within the pep-
tide binding groove and T cell receptor contact regions only:
the 6 hypervariable regions of the alpha-1 domain encoded
by exon 2 [2]. However, PIRCHE can also be derived from
polymorphic regions outside the peptide binding groove.
Inclusion of these polymorphic regions apparently enhances
the predictive capacity of the PIRCHE model when compared
with the TCE model. Inclusion of polymorphisms outside
exon 2 in an indirect model for antigen recognition is justi-
ﬁed by peptide elution data; DP-derived peptides encoded by
exon 1 have been frequently eluted from HLA (SYFPEITHI
database [http://www.syfpeithi.de/bin/MHCServer.dll/Find
YourMotif.htm], accessed May 2014). Because the PIRCHE
model considers a greater part of the HLA-DP alleles, it is a
more stringent model, consequently predicting clinically
relevant nonpermissibility at a higher frequency.
Investigating the interaction between the classical direct
recognition (TCE)model andourherenewlyproposed indirect
recognition (PIRCHE) model is of interest, because the 2
models theoretically aim to predict 2 different routes of DP-
antigen recognition. One could speculate that these 2 im-
mune responses are complementary or even enhance each
other in vivo. Hence, additive or even synergistic effects may
be expected. However, because of the strong correlation be-
tween the TCE and PIRCHE model in this study and the small
cohort size, interactions between the 2 models are difﬁcult to
test. Observations in thecurrent studymayeven implicate that
the PIRCHE model provides an explanation for the previous
ﬁndings of the TCE model, because all patients with a GVH
nonpermissive TCE mismatch had PIRCHE-I and -II. Future
studies conductedon largerpatient cohortsallowstudying the
interactionsbetweennonpermissivemismatches according to
theTCEmodel andpresenceof PIRCHEandwill elucidatewhat
the predictive capacity of the combination of these 2models is
or even if they truly predict independently.
Both the TCE and PIRCHE model have some practical
constraints. The TCE model is restricted by the fact that
cellular recognition patterns have not been determined for
all HLA-DP alleles. In our cohort, we could therefore not
predict permissiveness in 2 cases. To resolve this problem, it
is necessary to expand the immunogenicity predictions to
not yet tested HLA-DPB1 alleles, possibly in silico. The
PIRCHE model is limited by the requirement of full exon 1 to
6 sequences, because PIRCHE can also be derived from re-
gions outside exon 2. In the present study, the amino acidsequences of 4 HLA-DPB1 alleles (HLA-DPB1*20:01, 33:01,
36:01, 138:01) present in 10 individuals (6%) could only
partly be included in the PIRCHE model. We therefore may
have over- or underestimated the numbers of PIRCHE for
these pairs. Our study underlines the need for submission of
complete exon 1 to 6 sequences to the IMGT database to
prevent these gaps in the sequence knowledge. Such data
will allow more concise studying of the role of PIRCHE in
clinical outcomes.
Furthermore, the current study only predicts nonameric
PIRCHE-I. Although HLA class I molecules can bind peptides
of other lengths, the current HLA binding predictors are most
reliable for nonameric peptides. Future improvements on
binding predictions for non-nonameric peptides may facili-
tate studies on the effect of these non-nonameric PIRCHE-I.
The current study excludes HLA-DPA1ederived PIRCHE. It
is highly likely that many of the HLA-DPB1emismatched
pairs have an additional HLA-DPA1 mismatch, which could
lead to potential PIRCHE. Future studies should also include
analyzing the effect of HLA-DPA1ederived PIRCHE, which
may lead to further improvement of the predictive potential.
Mismatching for HLA-DP may lead to increased graft-
versus-leukemia effects, becasue HLA-DP is preferentially
expressed on the hematopoietic cell lineage [37]. Theoreti-
cally, high numbers of DP-derived PIRCHE as well as TCE
nonpermissive mismatches may lead to such an increased
antitumor effect. In the present study, we did not ﬁnd a
reduced relapse risk in patients with an increased chance of
alloreactivity targeting the HLA-DP mismatch (ie, TCE GVH
nonpermissive or high PIRCHE). In that perspective, it is
noteworthy that HLA-DP is expressed on the vast majority of
leukemic cells, but with considerable variety. For example,
HLA-DP expression is lower on AML than on B-ALL or B-CLL
cells [37]. Most acute leukemia patients in our study (82%)
suffered from acute myelogenous leukemia, a low HLA-DP
expressing leukemia. Research in speciﬁc disease sub-
groups is warranted to analyze the antitumor effect of TCE
nonpermissiveness and of high numbers of DP-derived PIR-
CHE to correct for differences in HLA-DP expression levels.
To conclude, our data show a correlation between indi-
rectly recognizable HLA-DP mismatches, as determined with
the PIRCHE model, and acute GVHD. These data might be
useful to complement currently used models for direct
recognition to provide a superior donor selection. Extended
studies on large cohorts are essential to reﬁne the integration
of these 2 models in donor-selection procedures, both with
respect to acute GVHD and graft-versus-leukemia effects,
and longer term effects like chronic GVHD and TRM.ACKNOWLEDGMENTS
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